Merck & Co., Inc. (MRK)[Tv]

Key Developments

• FDA grants Breakthrough Therapy designation to calderasib (MK-1084) in combination with Keytruda for first-line treatment of KRAS G12C-mutated metastatic NSCLC, marking a pivotal validation of Merck’s precision oncology strategy and accelerating development of a high-potential blockbuster therapy with transformative commercial upside.
• FDA approves expanded use of PD-L1 IHC 22C3 pharmDx diagnostic on Dako Omnis platform, strengthening Merck’s integrated diagnostic ecosystem and entrenching its control over KEYTRUDA’s patient selection—creating a self-reinforcing moat that enhances long-term commercial dominance across multiple cancers.
• Positive Phase 3 results in ISLEND-1 and ISLEND-2 trials for once-weekly oral HIV regimen (islatravir/lenacapavir) secured FDA Breakthrough Therapy designation, signaling a potential paradigm shift in HIV management and positioning Merck to challenge Gilead’s leadership in chronic infectious disease.
• FDA approval of Idvynso, a once-daily two-drug HIV regimen, cements Merck’s strategic expansion beyond oncology into high-growth infectious disease markets, demonstrating execution capability and opening a new revenue runway beyond Keytruda.
• EMA’s CHMP issues positive recommendation for Keytruda + Padcev combination in perioperative muscle-invasive bladder cancer (MIBC), representing a potential first-in-class PD-1 inhibitor + ADC combo in the EU, backed by robust Phase III data and signaling a major advance in bladder cancer care.